Halozyme Therapeutics, Inc. (NASDAQ:HALO), announced after the bell Wednesday that the FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer. The study can now resume under a revised protocol. Halozyme Therapeutics, Inc. (NASDAQ:HALO), weekly performance is 11.87%. On last trading day company shares ended up $9.05. Analysts mean target price for the company is $13.30. Halozyme Therapeutics, Inc. (NASDAQ:HALO), distance from 50-day simple moving average (SMA50) is 7.92%.
Clovis Oncology Inc (NASDAQ:CLVS), was downgraded by equities researchers at Citigroup Inc. from a “buy” rating to a “neutral” rating in a research report issued on Tuesday, TheFlyOnTheWall.com reports. They currently have a $53.00 target price on the stock, down from their previous target price of $109.00. Citigroup Inc.’s price target suggests a potential upside of 38.02% from the stock’s previous close. Clovis Oncology Inc (NASDAQ:CLVS), advanced 6.17% in last trading session and ended the day on $40.77. CLVS, return on assets is -19.80%. Clovis Oncology Inc (NASDAQ:CLVS), quarterly performance is -52.26%.
On May 31, 2014, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced plans for the clinical development of sapacitabine in a second potential indication for patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), shares in last trading session was closed at $2.93, while trading in range of $2.88 – 3.02. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), year to date (YTD) performance is -27.11%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares closed at $2.28. The company on May 30 announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company’s common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. Inovio Pharmaceuticals Inc (NYSEMKT:INO), ended the last trading day at $2.31. Company weekly volatility is calculated as 8.13% and price to cash ratio as 4.76. Inovio Pharmaceuticals Inc (NYSEMKT:INO), showed a negative weekly performance of 74.45%.
Illumina, Inc. (NASDAQ:ILMN), is up nearly 4% Thursday afternoon after the genetics and genotyping firm said late Wednesday it will sell $900 million aggregate principal amount of convertible senior notes. Illumina, Inc. (NASDAQ:ILMN), net profit margin is 13.80% and weekly performance is 2.64%. On last trading day company shares ended up $164.09. Analysts mean target price for the company is $176.97. Illumina, Inc. (NASDAQ:ILMN), distance from 50-day simple moving average (SMA50) is 12.49%.